Fulcrum Therapeutics to Present at the 31st Annual FSHD Society International Research Congress
Fulcrum Therapeutics (Nasdaq: FULC) will present at the 31st Annual FSHD Society International Research Congress in Denver, Colorado, on June 13-14, 2024. The presentations will cover various aspects of the Phase 3 REACH trial of losmapimod, a treatment for facioscapulohumeral muscular dystrophy (FSHD). Key presentations include an abstract on the baseline characteristics of trial participants, efficacy and progression of FSHD assessed by reachable workspace, and safety and tolerability of losmapimod. These findings will be disseminated through both poster and oral presentations, featuring various researchers, including Nicol Voermans, Joost Kools, Mihaela Levitchi Benea, and Lena Hubig.
- Fulcrum Therapeutics is actively participating in a prominent international research congress, enhancing visibility.
- Phase 3 REACH trial data for losmapimod will be shared, indicating advanced progress in clinical research.
- Multiple presentations cover various aspects of FSHD treatment, including efficacy, safety, and patient characteristics.
- Presence of experienced researchers and medical professionals in the presentations adds credibility.
- Availability of the presentation and posters online ensures broader access to the information.
- The press release does not provide specific clinical results or data, leaving investors without concrete updates on trial efficacy or safety.
- Absence of any financial data or revenue updates may leave shareholders concerned about the company's financial health.
- The focus on scientific presentations may not immediately translate to stock performance improvement or increased revenue.
CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced upcoming presentations to be made at the 31st Annual FSHD Society International Research Congress being held June 13-14, 2024 in Denver, Colorado, including an abstract outlining the baseline characteristics of patients enrolled in the Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD).
The presentations to be made are as follows:
Title: Characteristics of the Enrolled Population in the Phase 3 REACH Trial in Facioscapulohumeral Muscular Dystrophy (FSHD)
Poster Number: P7.01
Format: Poster
First Author: Nicol Voermans, MD, PhD, Radboud University Medical Center
Presentation Date and Time: Thursday, June 13, 2024, between 5:30-8:30 PM MDT
Title: Facioscapulohumeral Muscular Dystrophy (FSHD) Disease Progression and Losmapimod Efficacy Assessed by Reachable Workspace in Both Arms
Presentation Number: S6.06
Format: Oral presentation
Presenter: Joost Kools, MD, Radboud University Medical Center
Presentation Date and Time: Friday, June 14, 2024 at 3:50 PM MDT
Title: Safety and Tolerability of Losmapimod for the Treatment of FSHD
Poster Number: P6.05
Format: Poster
First Author: Mihaela Levitchi Benea, MD, Executive Director of Medical Affairs at Fulcrum Therapeutics
Presentation Date and Time: Thursday, June 13, 2024, between 5:30-8:30 PM MDT
Title: Reliability and Validity of Reachable Workspace Total Score with Wrist Weights in
Facioscapulohumeral Muscular Dystrophy
Poster Number: P7.06
Format: Poster
First Author: Lena Hubig, Acaster Lloyd Consulting
Presentation Date and Time: Thursday, June 13, 2024, between 5:30-8:30 PM MDT
The presentation and posters will be available on the publications page of Fulcrum’s website at https://www.fulcrumtx.com.
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s two lead programs in clinical development are losmapimod, a small molecule in development for the treatment of facioscapulohumeral muscular dystrophy (FSHD), and pociredir, a small molecule designed to increase expression of fetal hemoglobin and in development for the treatment of sickle cell disease (SCD) and other hemoglobinopathies. Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on Twitter/X (@FulcrumTx) and LinkedIn.
Contact:
Chris Calabrese
LifeSci Advisors, LLC
ccalabrese@lifesciadvisors.com
917-680-5608
FAQ
What will Fulcrum Therapeutics present at the 31st Annual FSHD Society International Research Congress?
When and where is Fulcrum Therapeutics presenting at the FSHD Society International Research Congress?
What is the focus of Fulcrum Therapeutics' Phase 3 REACH trial?
Will the presentations from Fulcrum Therapeutics be available online?
Who are some of the key presenters from Fulcrum Therapeutics at the congress?
